{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:28:00Z","timestamp":1782433680530,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2002,2]]},"DOI":"10.1067\/mhj.2002.120405","type":"journal-article","created":{"date-parts":[[2002,8,24]],"date-time":"2002-08-24T22:14:26Z","timestamp":1030227266000},"page":"229-234","source":"Crossref","is-referenced-by-count":50,"title":["Bivalirudin as a replacement for unfractionated heparin in unstable angina\/non-ST-elevation myocardial infarction: Observations from the TIMI 8 trial"],"prefix":"10.1067","volume":"143","author":[{"given":"Elliott M.","family":"Antman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn H.","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1067\/mhj.2002.120405_bib1","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0735-1097(00)00889-5","volume":"36","author":"Braunwald","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1067\/mhj.2002.120405_bib2","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/01.CIR.89.3.1449","article-title":"Guide to anticoagulant therapy, I: heparin","volume":"89","author":"Hirsh","year":"1994","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120405_bib3","first-page":"380S","article-title":"Antithrombotic agents in coronary artery disease","volume":"95","author":"Cairns","year":"1995","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120405_bib4","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.CIR.94.5.911","article-title":"Hirudin in acute myocardial infarction: thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial","volume":"94","author":"Antman","year":"1996","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120405_bib5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJM199609123351103","article-title":"A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes","volume":"335","author":"Global Use of Strategies to Open Occluded Coronary Arteries GUSTO IIb Investigators","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.120405_bib6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(98)07332-2","article-title":"Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: a randomised trial","volume":"353","author":"Organisation to Assess Strategies for Ischemic Syndromes OASIS-2 Investigators","year":"1999","journal-title":"Lancet"},{"key":"10.1067\/mhj.2002.120405_bib7","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-molecular-weight heparins","volume":"337","author":"Weitz","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.120405_bib8","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/0002-9149(93)90823-U","article-title":"Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease","volume":"71","author":"Cannon","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1067\/mhj.2002.120405_bib9","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1021\/bi00482a021","article-title":"Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin","volume":"29","author":"Maraganore","year":"1990","journal-title":"Biochemistry"},{"key":"10.1067\/mhj.2002.120405_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-0038-1651573","article-title":"Anticoagulant activity of hirulog, a direct thrombin inhibitor, in humans","volume":"69","author":"Fox","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1067\/mhj.2002.120405_bib11","first-page":"829","article-title":"Comparisons of antithrombin activities of heparin and hirulog-1: basis for improved antithrombotic properties of direct thrombin inhibitors","volume":"65","author":"Maraganore","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1067\/mhj.2002.120405_bib12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1161\/01.CIR.92.4.727","article-title":"Hirulog in the treatment of unstable angina: results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial","volume":"92","author":"Fuchs","year":"1995","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120405_bib13","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1161\/01.CIR.100.20.2049","article-title":"Clinical outcomes of bivalirudin for ischemic heart disease","volume":"100","author":"Kong","year":"1999","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120405_bib14","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(81)92399-0","article-title":"Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome","volume":"1","author":"Telford","year":"1981","journal-title":"Lancet"},{"key":"10.1067\/mhj.2002.120405_bib15","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin or both to treat unstable angina","volume":"319","author":"Theroux","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.120405_bib16","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.1996.03540100055028","article-title":"Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis","volume":"276","author":"Oler","year":"1996","journal-title":"JAMA"},{"key":"10.1067\/mhj.2002.120405_bib17","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/oxfordjournals.eurheartj.a015467","article-title":"A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients: a double-blind, randomized, dose-finding study","volume":"18","author":"Thrombin Inhibition in Myocardial Ischaemia TRIM Study Group","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1067\/mhj.2002.120405_bib18","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","article-title":"Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina: Hirulog Angioplasty Study Investigators","volume":"333","author":"Bittl","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1067\/mhj.2002.120405_bib19","doi-asserted-by":"crossref","first-page":"57P","DOI":"10.1016\/S0002-9149(98)00663-8","article-title":"Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion\/Occlusion (HERO-2) trial","volume":"82","author":"White","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1067\/mhj.2002.120405_bib20","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1161\/01.CIR.96.7.2155","article-title":"Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO): Hirulog Early Reperfusion\/Occlusion (HERO) Trial Investigators","volume":"96","author":"White","year":"1997","journal-title":"Circulation"},{"key":"10.1067\/mhj.2002.120405_bib21","doi-asserted-by":"crossref","first-page":"14807","DOI":"10.1021\/bi00253a020","article-title":"Kinetic mechanism for the interaction of Hirulog with thrombin","volume":"33","author":"Parry","year":"1994","journal-title":"Biochemistry"},{"issue":"E Suppl","key":"10.1067\/mhj.2002.120405_bib22","first-page":"27","article-title":"The mechanism of action of thrombin inhibitors","volume":"12","author":"Bates","year":"2000","journal-title":"J Invasive Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870302399265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870302399265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T01:46:02Z","timestamp":1576460762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870302399265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["S0002870302399265"],"URL":"https:\/\/doi.org\/10.1067\/mhj.2002.120405","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}